Active CD22 protein-coupled magnetic Beads

• Cat.No.: CD22-0945M

Specification

• Species: Human
• Appearance: Powder mixture
• Particle size: 2 μm
• Source: HEK293
• Protein length: Asp 20 - Arg 687
• Bio-activity: Immobilized 70μg Biotinylated Human CD22 protein to 1mg Beads can bind the Anti-CD22 Antibody with an EC50 0.7889 μg/mL.
• Coupled amount of protein: ≈505pmol (70μg) Siglec-2 protein/mg beads
• Capacity: >27pmol (2μg) Anti-hCD22 Ab/mg beads
• Formulation: PBS, pH7.4, with 10% Trehalose
• Reconstitution: 2 mL sterile deionized water (1 mg beads/mL)
• Background: The biotinylated CD22 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-CD22 antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This CD22 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
• Application: This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
• Storage: Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Reviews

01/15/2021

The CD22 protein offers numerous advantages in trials and research studies, making it an excellent choice for scientists in need of reliable and high-quality experimental materials.

06/15/2017

Its unique properties make CD22 an invaluable tool for investigating cellular signaling pathways, protein-protein interactions, and membrane dynamics.

02/17/2016

With the CD22 protein and its accompanying technical assistance, I am confident that I can achieve successful outcomes for my research endeavors.

Q&As

How does CD22-targeted immunotherapy differ from traditional chemotherapy?

CD22-targeted immunotherapy is more targeted, specifically attacking cancer cells, whereas chemotherapy affects both healthy and cancerous cells.

Can CD22-targeted therapies be used in combination with other cancer treatments?

Yes, CD22-targeted therapies are often used in combination with chemotherapy or other immunotherapies for enhanced efficacy.

What other diseases involve CD22 as a therapeutic target?

CD22-targeted therapies are being explored for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus.

Are there any clinical applications of CD22 protein in cancer therapy?

Yes, CD22 is targeted in immunotherapy for B cell malignancies like acute lymphoblastic leukemia (ALL).

What role does CD22 play in B cell function?

CD22 acts as an inhibitory receptor, regulating B cell activation and signaling.